News

Sight Sciences Announces the Closing of its $7MM Series B Financing Led by Hicks Equity Partners

September 22, 2016

Sight Sciences, Inc., a venture-backed, commercial-stage ophthalmic medical device company today announced it has closed a $7 million Series B round of financing. The round was led by Hicks Equity Partners, a leading private equity firm based in Dallas, Texas. All Series A investors participated in the oversubscribed Series B round, including Scientific Health Development (Series A Co-Lead), Allegro Investment Fund, and various other institutional and angel investors.

In The Media
January 14, 2025
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2024 Financial Highlights Read More
November 19, 2024
Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference Read More
November 7, 2024
Sight Sciences Reports Third Quarter 2024 Financial Results and Updates its Full Year 2024 Adjusted Operating Expense Guidance Read More
November 7, 2024
Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations Read More
October 18, 2024
Sight Sciences to Report Third Quarter Financial Results on November 7, 2024 Read More
August 20, 2024
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference Read More
August 1, 2024
Sight Sciences Reports Second Quarter 2024 Financial Results and Narrows Full Year 2024 Financial Guidance Read More
July 18, 2024
Sight Sciences to Report Second Quarter Financial Results on August 1, 2024 Read More
June 10, 2024
Sight Sciences Announces the Release of its First Sustainability Report Read More
May 28, 2024
Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma Read More

Want to speak to one of our representatives?

Contact Us